Policy & Regulation
New National Security Checks Could Hinder Investment, Warns UK Biotech Sector
Life science SMEs and their investors need to comply with new UK government checks on their dealmaking.
Novo Nordisk On The Pluses And Minuses Of The UK Post-Brexit R&D Environment
Post-Brexit Britain offers a fertile R&D ecosystem, but it needs to improve uptake in novel medicines there and strike a lasting deal with the EU over batch testing, Novo Nordisk’s UK general manager Pinder Sahota tells Scrip.
Policy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Policy
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.
WuXi AppTec Quits BIO As Group Endorses BIOSECURE Act
BIO chairman Ted Love had said at BIO CEO last month that “damaging” the company could have unintended consequences.
China Lowers GDP Target As VBP And Corruption In Focus At 'Two Sessions'
Amid slack domestic consumption and declining overseas demand, 2024 may be the start of a multi-year slowing in growth for the world’s second-largest economy. In the health sector, volume-based procurement continues to expand while the focus of anti-corruption campaigns appears to be changing.
Lilly CEO: Affordable Generics And IP Support 'Not Incompatible Ideas'
Lilly’s CEO indicates that the long-standing IPR debate that has generally divided the developed and developing world is largely a “false narrative”. The executive also called for lowering regulatory barriers in India amid expectations of the potential debut of Zepbound/Mounjaro in the country next year.
BIO Chair Ted Love On Drug Pricing And Political Pressure
Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.
Data Exclusivity Demand In EFTA-India Deal: Access, Licensing, Other Implications
The contentious issue of data exclusivity came to the fore during the European Free Trade Association's negotiations with India for a Free Trade Agreement. What are the arguments in support and against, including impact on compulsory and voluntary licensing?
Regulation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Regulation
Pipeline Watch: Six Approvals And 26 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
A Visual Trip Through The Psychedelic Pipeline
An infographic looking at the status and origins of 39 psychedelic drug development programs being pursued by 26 sponsors.
Pipeline Watch: Six Approvals And 18 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Four Approvals And 21 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
FDA Delay Will Not Push Rocket Pharma Off Its Trajectory
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.
Pipeline Watch: Eight Approvals And Five Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.